Botulinum Toxin Type A for Neuroma Pain
NCT01374191 is a phase 2 interventional trial sponsored by Southern Illinois University. As of 21 Nov 2026, it was withdrawn. It studies 2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A in Neuroma. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2015 and a primary completion date of 31 May 2017.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01374191 |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Southern Illinois University |
| Enrollment | 0 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Neuroma |
| Drugs | 2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A |
| Start | 31 Jan 2015 |
| Primary completion | 31 May 2017 |
| Study completion | 30 Sept 2017 |
| Last update posted | 26 Aug 2015 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Michael A. Neumeister, MD
Southern Illinois University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southern Illinois University School of Medicine
Springfield
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01374191
Each answer restates registry values shown on this page.
What is NCT01374191?
NCT01374191 is a phase 2 interventional trial sponsored by Southern Illinois University. It studies 2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A in Neuroma.
Who leads NCT01374191?
The registry names Michael A. Neumeister, MD (principal investigator, Southern Illinois University School of Medicine) as the overall official.
Where does NCT01374191 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01374191 study?
The registered drug and biological interventions are 2nd phase - onabotulinum toxin type-A and Onabotulinum toxin type-A.
When did NCT01374191 end?
The registry lists a primary completion date of 31 May 2017 and a study completion date of 30 Sept 2017. The sponsor last updated the record on 26 Aug 2015.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.